Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03564145 · ClinicalTrials.gov registry record · Phase 3
A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea
A Phase 3 study, sponsored by Sol-Gel Technologies.
- Terminated
- Registry status
- Phase 3
- Development phase
- 547
- Enrollment target
NCT03564145: Clinical Trial Phase 3 study, sponsored by Sol-Gel Technologies.
NCT03564145 is a Phase 3 study that was terminated before completion, run by Sol-Gel Technologies. The registered enrollment target is 547 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (29% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03564145, a Phase 3 study, was terminated before completion, sponsored by Sol-Gel Technologies.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 547 participants
- Enrollment target
Study Summary
To assess the safety of S5G4T-1 when applied once daily for up to 40 weeks in participants with papulopustular rosacea who completed either Study SGT-54-01 (NCT03448939) or Study SGT-54-02 (NCT03564119).
Primary Outcome
AE was defined as any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with the study drug. Abnormalities presented at Baseline were considered AEs if they reoccurred after resolution or worsen during the AE collection period. An SAE was defined as any AE that, in the view of either the Investigator or Sponsor, resulted in any of the following outcomes as fatal, life-threatening, required hospitalization or prolongation of existing hospitalizati
Interventions
- DRUG S5G4T-1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 547 participants |
| Start Date | 2018-09-12 |
| Est. Completion | 2019-11-13 |
| Phase | Phase 3 |
Why NCT03564145 stopped before completion
NCT03564145 is an interventional study that assigns participants to a tested intervention. The registered 547 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (29% lower).
The record links to 0 conditions, and to 1 intervention - of which S5G4T-1 is the first listed.
NCT03564145 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03564145 about?
NCT03564145 is a clinical study titled "A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea". To assess the safety of S5G4T-1 when applied once daily for up to 40 weeks in participants with papulopustular rosacea who completed either Study SGT-54-01 (NCT03448939) or Study SGT-54-02 (NCT03564119).
What is the current status of trial NCT03564145?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 547 participants. The study started on 2018-09-12. Estimated completion is 2019-11-13.
What interventions are being tested in trial NCT03564145?
The interventions under investigation include: S5G4T-1 (DRUG).
Who is sponsoring clinical trial NCT03564145?
This trial is sponsored by Sol-Gel Technologies, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03564145's enrollment target sits among peer trials
547 689th of 2000 higher than 1,312 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03572374 · 546 participants · NA
Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job
- NCT05937685 · 546 participants · NA
Reducing Blood Pressure in Patients With High Cardiovascular Risk
- NCT06416150 · 546 participants · NA
Reducing Urban Cervical Cancer Disparities
- NCT06850922 · 546 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI